Biotech News News 6 January 2026

Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week

New York, Jan 11, 2026, 08:01 EST — Market closed. Shares of Liquidia Corporation jumped 12.9% to close at $35.86 on Friday, following a strong sales surge for its inhaled treprostinil therapy, YUTREPIA. The stock traded between $29.41 and $38.07

11 January 2026

Biotech News·Earnings Reports·Investment Strategies·Pharmaceutical Industry·Stock Market

CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next

New York, January 11, 2026, 07:42 EST — Market closed CG Oncology shares jumped 29.26% on Friday, finishing at $54.20, setting a strong tone for Monday’s open. The boost came after the company announced it now anticipates Phase 3 PIVOT-006

11 January 2026

Biotech News·Clinical Trials·Investment Strategies·Stock Market

Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday

New York, January 10, 2026, 09:47 EST — Market closed Revolution Medicines shares jumped 10.7% to close at $118.64 on Friday, hitting a session high of $125.79 amid merger rumors. The Financial Times reported that Merck is negotiating a potential

10 January 2026

Biotech News·FDA Updates·Investment Insights·Stock Market

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

New York, January 9, 2026, 20:18 (EST) — Market closed AbbVie Inc. shares dropped 1.8% on Friday, closing at $220.08. The decline followed the drugmaker’s decision to lower its 2025 earnings forecast and a denial of reports suggesting it was

10 January 2026

Biotech News·Financial Analysis·Investing·Pharmaceutical Industry·Stock Market

Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

New York, Jan 9, 2026, 14:36 (EST) — Regular session Nuvation Bio Inc (NUVB) shares slid about 4.7% to $8.05 Friday afternoon, after earlier hitting a session low of $8.05. The stock’s pullback follows new sell-side takes on a name

9 January 2026

Biotech News·Investment Insights·Stock Market

Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

New York, January 8, 2026, 14:40 EST — Regular session Arcus Biosciences (RCUS) shares slid 9.3% to $21.05 in afternoon trading on Thursday, after earlier touching $22.70. The stock hit a session low of $21.02. Morgan Stanley cut its rating

8 January 2026

Biotech News·Financial Updates·Investment Analysis·Pharmaceutical Industry·Stock Market

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

NEW YORK, Jan 8, 2026, 08:59 (EST) — Premarket Omeros Corp (OMER.O) shares were up 0.55, or about 4%, at $14.09 in premarket trade on Thursday after the drugmaker set a $36,000 price for each single-dose vial of its newly

8 January 2026

Biotech News·Drug Pricing·Financial News·Pharmaceuticals·Stock Market

Legend Biotech (LEGN) stock jumps after Oppenheimer starts coverage with $75 target

New York, January 7, 2026, 12:32 (EST) — Regular session Shares of Legend Biotech Corp rose 7.4% to $22.53 in midday trading on Wednesday after Oppenheimer initiated coverage with an “Outperform” rating and set a $75 price target, according to

7 January 2026

Analyst Ratings·Biotech News·Financial Updates·Investment·Stock Market

Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

New York, Jan 7, 2026, 11:10 EST — Regular session Shares of Abivax SA jumped 7.3% to $127.75 in morning trading on Wednesday, after touching a session high of $128.87 and a low of $119.48. Trading volume topped 700,000 shares.

7 January 2026

Biotech News·Financial Analysis·Investing·Nasdaq·Stock Market

Ventyx Biosciences stock jumps premarket as Eli Lilly buyout talks fuel takeover buzz

New York, Jan 7, 2026, 05:03 EST — Premarket Ventyx Biosciences shares jumped about 66% before the bell on Wednesday after a report that Eli Lilly is in advanced talks to buy the biotech company for more than $1 billion.

7 January 2026

Biotech News·Investment·Mergers and Acquisitions·Pharma Industry·Stock Market

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

New York, January 6, 2026, 15:27 (ET) — Regular session Nasdaq-listed Travere Therapeutics shares fell 5.3% to $36.09 in afternoon trading on Tuesday as investors looked toward next week’s U.S. FDA decision deadline on expanding its kidney drug Filspari (sparsentan)

6 January 2026

Biotech News·FDA Updates·Investment Analysis·Pharmaceutical Industry·Stock Market

Johnson & Johnson stock ticks up on lupus drug data as earnings loom

New York, January 6, 2026, 12:58 EST — Regular session Johnson & Johnson (JNJ.N) shares rose on Tuesday after the company reported positive mid-stage data for its experimental lupus drug nipocalimab and outlined plans for late-stage testing. The stock was

6 January 2026

Biotech News·Earnings Reports·Healthcare Industry·Pharmaceuticals·Stock Market

Biotech News News 6 January 2026 - 11 January 2026